RecruitingPhase 2NCT06904872

Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)

Studying Short bowel syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Napo Therapeutics, S.p.A.
Intervention: Crofelemer Powder for Oral Solution(drug)
Enrollment: 18 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2026

Study locations (8)

Universitäatsklinik RWTH, Aachen, Germany
Charité Universitätsmedizin, Berlin, Germany
Universitätsklinikum, Essen, Germany
Asklepios Klinik St. Georg, Hamburg, Germany
Universitätsmedizin, Rostock, Germany
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy
Azienda Ospedaliera Universitaria Federico II, Naples, Italy
Ospedale Università di Padova, Padua, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06904872 on ClinicalTrials.gov

Other trials for Short bowel syndrome

Additional recruiting or active studies for the same condition.

See all trials for Short bowel syndrome →

← Back to all trials